MARKET

NAVB

NAVB

NAVIDEA BIOPHARM
AMEX

Real-time Quotes | Nasdaq Last Sale

2.300
+0.020
+0.88%
Opening 14:30 12/04 EST
OPEN
2.300
PREV CLOSE
2.280
HIGH
2.340
LOW
2.276
VOLUME
67.10K
TURNOVER
--
52 WEEK HIGH
5.36
52 WEEK LOW
0.6300
MARKET CAP
61.38M
P/E (TTM)
-4.4479
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Navidea Biopharmaceuticals Inc (NAVB) A Good Stock To Buy?
Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
Insider Monkey · 11/26 23:34
CVS Health, Walgreens Boots Alliance among major healthcare premarket losers' pack
Brainstorm Cell Therapeutics (BCLI) -69% after announcing topline results from Phase 3 trial evaluating NurOwn.Alterity Therapeutics (ATHE) -24%.iBio (IBIO) -20% on FQ1 earnings release.The Alkaline Water Company (WTER) -17% on FQ2 earnings release.GoodRx Holdings (GDRX) -18% tumble after
Seekingalpha · 11/17 14:01
CSCO, NIO, DKNG and VIPS among premarket gainers
Urovant Sciences (UROV) +93% as Sumitovant Biopharma to acquire balance shares for $16.25/share.CBAK Energy Technology (CBAT) +55%.Hall of Fame Resort & Entertainment (HOFV) +37% after providing update on the Inaugural NFL Alumni Academy.Li Auto (LI) +29% on
Seekingalpha · 11/13 13:27
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
LI, AMWL, FTCH and REV among after-hours movers
Gainers: [[UROV]] +91.4%. [[NAVB]] +30%. [[AWX]] +20.4%. [[FTCH]] +13.2%. [[LI]] +11.2%.Losers: [[GFF]] -10.4%. [[REV]] -7%. [[UUU]] -6%. [[AMWL]] -5.3%. [[LMNL]] -4.1%.
Seekingalpha · 11/12 22:43
Navidea imaging agent shows predictive value in rheumatoid arthritis
Navidea Biopharmaceuticals (NAVB) announces encouraging data from the third arm in a Phase 2b clinical trial evaluating imaging agent Tc99m tilmanocept in patients with active rheumatoid arthritis ((RA)).The third arm
Seekingalpha · 11/12 21:21
Navidea Biopharm EPS misses by $0.04, beats on revenue
Navidea Biopharm (NAVB): Q3 GAAP EPS of -$0.13 misses by $0.04.Revenue of $0.27M (+12.5% Y/Y) beats by $0.12M.Ended the quarter with $3.7M in cash and equivalents.Shares +43.75%.Press Release
Seekingalpha · 11/12 21:12
Navidea Biopharmaceutical Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $268.00K Beat $150.00K Estimate
Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 23.53 percent increase over losses of $(0.17) per
Benzinga · 11/12 21:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NAVB. Analyze the recent business situations of NAVIDEA BIOPHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NAVB stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 742.82K
% Owned: 2.78%
Shares Outstanding: 26.69M
TypeInstitutionsShares
Increased
7
158.08K
New
5
36.74K
Decreased
8
25.91K
Sold Out
24
84.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.45%
Pharmaceuticals & Medical Research
+1.41%
Key Executives
Chairman/Independent Director
Michael Rice
Chairman/Independent Director
Y. Michael Rice
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Independent Director
Claudine Bruck
Independent Director
Adam Cutler
Independent Director
Kathy Rouan
Independent Director
S. Kathryn Rouan
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.